Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Hong-wu Chen"'
Autor:
Pengfei Xu, Joy C. Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T. Johnson, Gabriela Grigorean, Brett Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G. Tepper, Hong-Wu Chen, Christopher P. Evans, Marc A. Dall’Era, Allen C. Gao, Jason E. Gestwicki, Chengfei Liu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract N-Myc is a key driver of neuroblastoma and neuroendocrine prostate cancer (NEPC). One potential way to circumvent the challenge of undruggable N-Myc is to target the protein homeostasis (proteostasis) system that maintains N-Myc levels. Here
Externí odkaz:
https://doaj.org/article/7245d627558b40309015d3fca64f4865
Autor:
Jie Xu, Hao Hu, Dan li, Hong-Wu Chen, Jiawei Wu, Yu-Wei Wang, Likun Ma, Jing-Sheng Hua, Xiang-Yong Kong, Long-Wei Li, Jian-Yuan Pan
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Introduction Patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) and concomitant multivessel coronary artery disease (CAD) are considered patients with extremely high-risk atherosclerotic cardiovascular disease (ASCVD), and curr
Externí odkaz:
https://doaj.org/article/42d5de3cc0d34eb09143f830b251943d
Autor:
Jia-Luo Huang, Xue-Long Yan, Dong Huang, Lu Gan, Huahua Gao, Run-Zhu Fan, Shen Li, Fang-Yu Yuan, Xinying Zhu, Gui-Hua Tang, Hong-Wu Chen, Junjian Wang, Sheng Yin
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 12, Pp 4934-4944 (2023)
Nuclear transporter importin-β1 is emerging as an attractive target by virtue of its prevalence in many cancers. However, the lack of druggable inhibitors restricts its therapeutic proof of concept. In the present work, we optimized a natural import
Externí odkaz:
https://doaj.org/article/6fc49276dc944b37a9e55038536ea213
Autor:
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong-Wu Chen, Huichang Bi, Ai-Ming Yu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 10, Pp 4273-4290 (2023)
During the development of therapeutic microRNAs (miRNAs or miRs), it is essential to define their pharmacological actions. Rather, miRNA research and therapy mainly use miRNA mimics synthesized in vitro. After experimental screening of unique recombi
Externí odkaz:
https://doaj.org/article/f4d6176f67c746b9918b7333fa7e1e5b
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundGestational diabetes mellitus (GDM), a transient disease, may lead to short- or long-term adverse influences on maternal and fetal health. Therefore, its potential functions, mechanisms and related molecular biomarkers must be comprehended
Externí odkaz:
https://doaj.org/article/e5beefb62def41698687cad957dbbaef
Autor:
Shu Ning, Jinge Zhao, Alan P. Lombard, Leandro S. D’Abronzo, Amy R. Leslie, Masuda Sharifi, Wei Lou, Chengfei Liu, Joy C. Yang, Christopher P. Evans, Eva Corey, Hong-Wu Chen, Aiming Yu, Paramita M. Ghosh, Allen C. Gao
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-12 (2022)
Ning et al. report expression of a neural lineage gene signature in enzalutamide-resistant prostate cancer cells and datasets from patients with neuroendocrine prostate cancer. One of these genes, ARHGEF2, is associated with poor overall and disease-
Externí odkaz:
https://doaj.org/article/23a69cb8d6894a2792a756ea7fe5a961
Autor:
Bo Chen, William J Murphy, Xiong Zhang, Pengfei Xu, Chengfei Liu, Joy C Yang, Christopher Nip, Jonathan E Van Dyke, Hong-Wu Chen, Christopher P Evans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial reve
Externí odkaz:
https://doaj.org/article/8f5213ee1f4342c4a2bb4d14ef4772c7
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Natural compounds ursolic acid (UA) and digoxin isolated from fruits and other plants display potent anti-cancer effects in preclinical studies. UA and digoxin have been at clinical trials for treatment of different cancers including prostate cancer,
Externí odkaz:
https://doaj.org/article/678cd8a39bd944cb8488cd8b99499f1d
Autor:
Hong Wang, Qianqian Wang, Guodi Cai, Zhijian Duan, Zoann Nugent, Jie Huang, Jianwei Zheng, Alexander D. Borowsky, Jian Jian Li, Peiqing Liu, Hsing-Jien Kung, Leigh Murphy, Hong-Wu Chen, Junjian Wang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 4, Pp 1871-1884 (2022)
Metabolic and epigenetic reprogramming play important roles in cancer therapeutic resistance. However, their interplays are poorly understood. We report here that elevated TIGAR (TP53-induced glycolysis and apoptosis regulator), an antioxidant and gl
Externí odkaz:
https://doaj.org/article/538925d98d464283b8a69c88387e94f7
Autor:
Nian Jiang, Bowen Xie, Wenwu Xiao, Ming Fan, Shanxiu Xu, Yixin Duan, Yamah Hamsafar, Angela C. Evans, Jie Huang, Weibing Zhou, Xuelei Lin, Ningrong Ye, Siyi Wanggou, Wen Chen, Di Jing, Ruben C. Fragoso, Brittany N. Dugger, Paul F. Wilson, Matthew A. Coleman, Shuli Xia, Xuejun Li, Lun-Quan Sun, Arta M. Monjazeb, Aijun Wang, William J. Murphy, Hsing-Jien Kung, Kit S. Lam, Hong-Wu Chen, Jian Jian Li
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
Acquired radioresistance is a challenge for the cure of glioblastoma. Here, the authors show that radioresistant glioblastoma boosts mitochondrial fatty acid oxidation that fuels cell proliferation and induces immunosuppression via CD47 mediated anti
Externí odkaz:
https://doaj.org/article/9ea4ad505be945a8af46118fb26c43d3